Cernevit

DRUG3 trials

Sponsors

Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken, Medical University Of Vienna, CHRU De Nancy, Centre Hospitalier Universitaire Dijon

Conditions

Acute Decompensated Heart FailureCardiogenic Shock

Phase 2

Effects of Levosimendan in patients being weaned from venoarterial extracorporal membrane oxygenation. A randomized controlled investigator driven phase II trial

RecruitingCTIS2023-508024-36-00

Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken, Medical University Of ViennaCardiogenic Shock

Start: 2024-07-05Target: 46Updated: 2024-03-11

Phase 3

Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS

TerminatedNCT04158674

Centre Hospitalier Universitaire DijonAcute Decompensated Heart Failure

Start: 2020-02-24End: 2023-10-11Updated: 2026-02-03

Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock

RecruitingCTIS2024-513811-29-00

CHRU De NancyCardiogenic Shock

Start: 2023-07-03Target: 610Updated: 2025-07-30

Related Papers

Short- and Long-Term Efficacy and Safety of Levosimendan in VA-ECMO Weaning: The WEANILEVO Randomized Double-Blind Multicenter Trial

Anesthesiology2026-05-08